Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02777710||Recruiting||Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers||
||Other / Industry||
||58||All||18 Years and older (Adult, Older Adult)||NCT02777710||ET15-037 (MEDIPLEX)
|MEDIPLEX||June 2016||September 2018||June 2019||May 19, 2016||December 20, 2017||